You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Accelerating Metagenomics Using Graphics Processing Units
SBC: Multicoreware, Inc. Topic: 35aA key application of the technological breakthrough associated with decreased cost of DNA sequencing is metagenomics. Metagenomics is the process of sequencing DNA from whole ecosystems, rather than individuals or cultures. This approach has the potential to allow the dissection of microbial ecosystems in biofuel producing agricultural land, toxic contaminated sites and hydrocarbon recovery enviro ...
STTR Phase I 2010 Department of Energy -
A Concrete Additive Manufacturing Process for Fixed and Floating Wind Turbine Foundations and Towers
SBC: JC Solutions Topic: 14bTall towers and foundations for modern offshore and land-based wind turbines are too large to transport over roads or rail due to their extremely large dimensions. Existing “one-off” on-site construction methods are too expensive, and are too slow for manufacturing foundations and towers in the large numbers needed, especially for offshore components manufactured in ports with limited lay-down ...
STTR Phase I 2018 Department of Energy -
A cost-effective bioreactor to advance functional tissue engineering of cartilage
SBC: Apex Biomedical Company, LLC Topic: NIAMSDESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies. Although TE cartilage presently lacks the mechanical stability of native cartilage, studies have demonstrated that mechanical stability can be e ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Acute-infarct selective cardiac MRI contrast agent
SBC: ELGAVISH PARAMAGNETICS, INC. Topic: NHLBIDESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy
SBC: Neuro Devices, Inc. Topic: 107DESCRIPTION provided by applicant We devised a new generation highly sensitivity method to diagnosis peripheral neuropathy early when the probability for reversal is greatest Cancer chemotherapy and diabetes are the most common causes of neuropathy in the USA Both cause decreased sweating abnormal circulation peripheral numbness pain and weakness If diagnosed early both are potentially ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Administrative Supplement to restore fee funds
SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. Topic: NINDSProject Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma
SBC: Avenzoar Pharmaceuticals, Inc. Topic: 102ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Advance Additive Manufacturing Method for SRF Cavities of Various Geometries
SBC: RADIABEAM TECHNOLOGIES, LLC Topic: 34aCurrent state-of-the-art SRF accelerating cavities require the use of many complex and expensive techniques throughout their fabrication/performance cycle. This project will utilize a novel Additive Manufacturing (AM) process to produce nearly monolithic SRF niobium cavities of arbitrary shape with features such as optimized wall thickness and/or integrated stiffeners, greatly reducing the cost a ...
STTR Phase II 2013 Department of Energy -
Advanced Spectroscopic Capabilities for 3-D Synchrotron X-Ray Microscopes
SBC: Xradia Topic: 09aMany important technology challenges today such as the capacity and life time of batteries require new characterization techniques to understand and improve performance. In the STTR Phase II project, novel x-ray microscope techniques and software are developed to be able to image samples in three dimensions and determine chemical composition and function on a microscopic level. As known from ubi ...
STTR Phase II 2013 Department of Energy -
Advancing clemizole for hepatitis C: towards a pre-IND package
SBC: EIGER GROUP INTERNATIONAL, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health